- |||||||||| Xtandi (enzalutamide capsule) / Pfizer, Astellas
No Pressure: An Unusual Case of PFO Induced Hypoxia (San Diego Convention Center, Area I (Hall H, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_6424; pneumonectomy, dilated descending aorta, compression from the abdomen, kyphosis) have been described. Knowledge of this phenomenon can be critical in making a diagnosis in an otherwise challenging case.
- |||||||||| leuprolide acetate for depot suspension / Generic mfg.
Trial completion date, Trial primary completion date: A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty (clinicaltrials.gov) - Feb 15, 2024 P4, N=80, Recruiting, Trial primary completion date: Jul 2028 --> Sep 2029 Trial completion date: Apr 2024 --> May 2025 | Trial primary completion date: Jan 2024 --> May 2025
- |||||||||| Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Enrollment open, HEOR: RecoverPC: Relugolix vs GnRH Agonist in Quality of Life (clinicaltrials.gov) - Feb 14, 2024 P2, N=110, Recruiting, These consensus statements serve as a practical recommendation for clinicians in Hong Kong, and possibly the Asia-Pacific region, in the management of cardiometabolic toxicities of ADT or AR axis-targeted therapies in men with PCa. Not yet recruiting --> Recruiting
- |||||||||| Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Enrollment closed, Adverse events: REPLACE-CV: Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate (clinicaltrials.gov) - Jan 28, 2024 P3, N=2250, Active, not recruiting, Our results suggest that melatonin can inhibit the hypothalamic-pituitary-gonadal (HPG) axis by down-regulating the Kiss-1/Kiss1R system, thereby treating CPP in female mice. Recruiting --> Active, not recruiting
- |||||||||| CARDIAC REHABILITATION FOR TRANSGENDER PATIENT: CASE REPORT (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_473;
Interestingly, CR did not improve body composition in this patient. Despite the clear positive impact that CR had on exercise capacity, body composition appeared to worsen.
- |||||||||| emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Trial completion date, Trial primary completion date: Pre-Exposure Prophylaxis (PrEP)- Gender Affirming Hormone Therapy (GAHT) Interactions in TGW (clinicaltrials.gov) - Jan 11, 2024 P1, N=20, Recruiting, expression and ameliorate RGC dysfunction, providing preclinical proof-of-concept evidence supporting novel neuroprotective strategies for NF1-OPG-induced vision loss. Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Mar 2024 --> Mar 2025
- |||||||||| leuprolide acetate for depot suspension / Generic mfg.
Journal: The multifactorial aetiology and management of premenstrual dysphoric disorder with leuprorelin acetate. (Pubmed Central) - Jan 6, 2024 As the psychological nature and consequences of PMDD often seem indistinguishable from symptoms of other mental health difficulties, this condition presents distinct diagnostic challenges for healthcare professionals. It is crucial to establish the correct diagnosis using clearly defined criteria because if it is left untreated, it can cause considerable impairment to the woman's quality of life.
- |||||||||| Kepivance (palifermin) / SOBI, Amgen, Firmagon (degarelix) / Astellas, Ferring
Trial completion date, Trial primary completion date: Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - Jan 4, 2024 P2, N=82, Active, not recruiting, It is crucial to establish the correct diagnosis using clearly defined criteria because if it is left untreated, it can cause considerable impairment to the woman's quality of life. Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
- |||||||||| leuprolide acetate for depot suspension / Generic mfg., abiraterone acetate / Generic mfg.
Journal: Scalp nodules as the first presentation of prostate cancer: A CARE-compliant article. (Pubmed Central) - Dec 24, 2023 Cutaneous metastasis, especially scalp metastasis from prostate cancer, is extremely rare. If there is a rash or nodule on the skin, it is necessary to evaluate it carefully and to confirm it through a biopsy.
- |||||||||| Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Trial initiation date, HEOR: RecoverPC: Relugolix vs GnRH Agonist in Quality of Life (clinicaltrials.gov) - Dec 19, 2023 P2, N=110, Not yet recruiting, If there is a rash or nodule on the skin, it is necessary to evaluate it carefully and to confirm it through a biopsy. Initiation date: Aug 2023 --> Jan 2024
- |||||||||| leuprolide acetate for depot suspension / Generic mfg.
Pattern of testosterone recovery after androgen deprivation therapy. (Level 1, West Hall; Poster Bd # N21) - Dec 13, 2023 - Abstract #ASCOGU2024ASCO_GU_480; Risk factors for non-recovery include age >80 years and long-term ADT use. Surprisingly, among men who achieved testosterone recovery, there was no difference in TTR with respect to ADT duration.
- |||||||||| enzalutamide capsule / Generic mfg., leuprolide acetate for depot suspension / Generic mfg.
EMBARK post hoc analysis of sexual activity (SA) patient-reported outcome (PRO) measures. (Level 1, West Hall; Poster Bd # N4) - Dec 13, 2023 - Abstract #ASCOGU2024ASCO_GU_463; P3 Further, the SA PROs were similar between ENZ + L and P + L, implying there is no further SA burden when adding ENZ to androgen-deprivation therapy. Clinical trial information: NCT02319837.
- |||||||||| Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Relugolix versus leuprolide in combination with radiotherapy for localized prostate cancer (REVELUTION trial): An initial analysis of patient treatment preferences and quality of life. (Level 1, West Hall; Poster Bd # M14) - Dec 13, 2023 - Abstract #ASCOGU2024ASCO_GU_451; P4 Relugolix, compared with leuprolide, mitigated acute urinary toxicity from XRT, perhaps due to superior castration resulting in greater prostate gland downsizing and less obstructive uropathy. Longer-term follow up is ongoing, and primary CV toxicity endpoint is expected to be complete in 2024.
- |||||||||| leuprolide acetate for depot suspension / Generic mfg.
Journal: Electrochemical Modification of Polypeptides at Selenocysteine. (Pubmed Central) - Dec 7, 2023 The power of e-SE is highlighted through late-stage C-terminal modification of the FDA-approved cancer drug leuprolide, and assembly of a library of anti-HER2 affibody-conjugates bearing complex cargoes. Following assembly by e-SE, the utility of functionalized affibodies for in vitro imaging and targeting of HER2 positive breast and lung cancer cell lines is also demonstrated.
- |||||||||| tamoxifen / Generic mfg.
Trial completion date, Trial primary completion date: Density Lowering Effect of "OFS Add on to TMX"(DELFINO Trial) (clinicaltrials.gov) - Dec 4, 2023 P3, N=224, Recruiting, . Trial completion date: Oct 2023 --> Dec 2024 | Trial primary completion date: Sep 2023 --> Dec 2024
- |||||||||| NN1213 / Novo Nordisk
Trial completion, Trial completion date, Trial primary completion date: Brown Adipose Tissue Activity in Pre- and Postmenopausal Women (clinicaltrials.gov) - Dec 4, 2023 P=N/A, N=72, Completed, Trial completion date: Oct 2023 --> Dec 2024 | Trial primary completion date: Sep 2023 --> Dec 2024 Recruiting --> Completed | Trial completion date: Aug 2023 --> May 2023 | Trial primary completion date: Aug 2023 --> May 2023
- |||||||||| Xtandi (enzalutamide capsule) / Pfizer, Astellas, Rubraca (rucaparib) / Pharma& Schweiz
Enrollment closed, Enrollment change, Metastases: CASPAR: A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy (clinicaltrials.gov) - Dec 3, 2023 P3, N=61, Active, not recruiting, Recruiting --> Completed | Trial completion date: Aug 2023 --> May 2023 | Trial primary completion date: Aug 2023 --> May 2023 Suspended --> Active, not recruiting | N=1002 --> 61
- |||||||||| Firmagon (degarelix) / Astellas, Ferring, NN1213 / Novo Nordisk
Phase classification, Monotherapy: High-Dose Brachytherapy in Treating Patients With Prostate Cancer (clinicaltrials.gov) - Nov 21, 2023 P=N/A, N=163, Active, not recruiting, Here, we formulated drug-free microspheres from two kinds of uncapped poly(lactide-co-glycolides) (PLGAs), i.e., ring-opening polymerized Expansorb DLG 50-2A (50/50, 11.2 Phase classification: P1/2 --> P=N/A
- |||||||||| Esmya (ulipristal acetate) / ASKA Pharma, Gedeon Richter, AbbVie, Perrigo Company, Cetrotide (cetrorelix) / EMD Serono, Mifeprex (mifepristone) / Danco Laboratories
Review, Journal: Novel Approaches to Possible Targeted Therapies and Prophylaxis of Uterine Fibroids. (Pubmed Central) - Nov 21, 2023 Three different nosological forms of the disease associated with driver mutations in the MED12, HMGA2, and FH genes should be considered when developing or prescribing drugs. For example, synthetic inhibitors and vaccines based on matrix metalloproteinases MMP11 and MMP16 are expected to be effective only for the prevention of the occurrence of MED12-dependent nodules.
- |||||||||| Xtandi (enzalutamide) / Pfizer, Astellas
Enrollment open: ARCH: Contributions to Hypertension With Androgen Deprivation Therapy (clinicaltrials.gov) - Nov 18, 2023 P4, N=228, Recruiting, For example, synthetic inhibitors and vaccines based on matrix metalloproteinases MMP11 and MMP16 are expected to be effective only for the prevention of the occurrence of MED12-dependent nodules. Not yet recruiting --> Recruiting
|